Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis

Yumi Ito, Hiroshi Kawachi, Yoshio Morioka, Takesshi Nakatsue, Hiroko Koike, Yohei Ikezumi, Akihisa Oyanagi, Yasuhiro Natori, Yumiko Natori, Takamichi Nakamura, Fumitake Gejyo, Fujio Shimizu

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. We established the reversible and the prolonged models of mesangial proliferative glomerulonephritis (GN) with anti-Thy 1 antibody 1-22-3. However, the essential factors leading to the prolonged glomerular alterations have not been identified. Methods. The expressions of several chemokines and cytokines were compared in the reversible and the prolonged models. Expression of fractalkine and the number of the fractalkine receptor CX 3 CRl-positive cells in the glomeruli in the prolonged model were significantly higher than those in the reversible model. Then, the localization of fractalkine and the characteristics of CX 3 CR1 + cells were analyzed in glomeruli. To elucidate the significance of the fractalkine expression, we analyzed the expression in the model treated with angiotensin II receptor antagonist, candesartan. Results. Immunostaining of fractalkine was detected on endothelial cells on the fifth day, and fractalkine staining also was detected in the mesangial area on day 14. Major parts of the CX 3 CR1 + cells in the glomeruli were macrophages, especially ED3 + cells. Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction. Although the treatment did not ameliorate the morphological finding at two weeks, decreased expression of fractalkine and CX 3 CR1 + were already detected at two weeks in rats treated with candesartan. Conclusions. Fractalkine expression and the recruitment of CX 3 CR1 + cells in glomeruli might play an important role in the development of the prolonged disease. These expressions could be predictors of the prolonged disease of the mesangial proliferative glomerulonephritis.

Original languageEnglish
Pages (from-to)2044-2057
Number of pages14
JournalKidney International
Volume61
Issue number6
DOIs
Publication statusPublished - 01-01-2002

Fingerprint

Chemokine CX3CL1
Glomerulonephritis
Angiotensin Receptor Antagonists
V28 receptor
Chemokines
Endothelial Cells
Macrophages
Staining and Labeling
Cytokines

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Ito, Yumi ; Kawachi, Hiroshi ; Morioka, Yoshio ; Nakatsue, Takesshi ; Koike, Hiroko ; Ikezumi, Yohei ; Oyanagi, Akihisa ; Natori, Yasuhiro ; Natori, Yumiko ; Nakamura, Takamichi ; Gejyo, Fumitake ; Shimizu, Fujio. / Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis In: Kidney International. 2002 ; Vol. 61, No. 6. pp. 2044-2057.
@article{262d77ecc246437ba5d94bc59d5839f3,
title = "Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis",
abstract = "Background. We established the reversible and the prolonged models of mesangial proliferative glomerulonephritis (GN) with anti-Thy 1 antibody 1-22-3. However, the essential factors leading to the prolonged glomerular alterations have not been identified. Methods. The expressions of several chemokines and cytokines were compared in the reversible and the prolonged models. Expression of fractalkine and the number of the fractalkine receptor CX 3 CRl-positive cells in the glomeruli in the prolonged model were significantly higher than those in the reversible model. Then, the localization of fractalkine and the characteristics of CX 3 CR1 + cells were analyzed in glomeruli. To elucidate the significance of the fractalkine expression, we analyzed the expression in the model treated with angiotensin II receptor antagonist, candesartan. Results. Immunostaining of fractalkine was detected on endothelial cells on the fifth day, and fractalkine staining also was detected in the mesangial area on day 14. Major parts of the CX 3 CR1 + cells in the glomeruli were macrophages, especially ED3 + cells. Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction. Although the treatment did not ameliorate the morphological finding at two weeks, decreased expression of fractalkine and CX 3 CR1 + were already detected at two weeks in rats treated with candesartan. Conclusions. Fractalkine expression and the recruitment of CX 3 CR1 + cells in glomeruli might play an important role in the development of the prolonged disease. These expressions could be predictors of the prolonged disease of the mesangial proliferative glomerulonephritis.",
author = "Yumi Ito and Hiroshi Kawachi and Yoshio Morioka and Takesshi Nakatsue and Hiroko Koike and Yohei Ikezumi and Akihisa Oyanagi and Yasuhiro Natori and Yumiko Natori and Takamichi Nakamura and Fumitake Gejyo and Fujio Shimizu",
year = "2002",
month = "1",
day = "1",
doi = "10.1046/j.1523-1755.2002.00369.x",
language = "English",
volume = "61",
pages = "2044--2057",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

Ito, Y, Kawachi, H, Morioka, Y, Nakatsue, T, Koike, H, Ikezumi, Y, Oyanagi, A, Natori, Y, Natori, Y, Nakamura, T, Gejyo, F & Shimizu, F 2002, ' Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis ', Kidney International, vol. 61, no. 6, pp. 2044-2057. https://doi.org/10.1046/j.1523-1755.2002.00369.x

Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis . / Ito, Yumi; Kawachi, Hiroshi; Morioka, Yoshio; Nakatsue, Takesshi; Koike, Hiroko; Ikezumi, Yohei; Oyanagi, Akihisa; Natori, Yasuhiro; Natori, Yumiko; Nakamura, Takamichi; Gejyo, Fumitake; Shimizu, Fujio.

In: Kidney International, Vol. 61, No. 6, 01.01.2002, p. 2044-2057.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fractalkine expression and the recruitment of CX 3 CR1 + cells in the prolonged mesangial proliferative glomerulonephritis

AU - Ito, Yumi

AU - Kawachi, Hiroshi

AU - Morioka, Yoshio

AU - Nakatsue, Takesshi

AU - Koike, Hiroko

AU - Ikezumi, Yohei

AU - Oyanagi, Akihisa

AU - Natori, Yasuhiro

AU - Natori, Yumiko

AU - Nakamura, Takamichi

AU - Gejyo, Fumitake

AU - Shimizu, Fujio

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background. We established the reversible and the prolonged models of mesangial proliferative glomerulonephritis (GN) with anti-Thy 1 antibody 1-22-3. However, the essential factors leading to the prolonged glomerular alterations have not been identified. Methods. The expressions of several chemokines and cytokines were compared in the reversible and the prolonged models. Expression of fractalkine and the number of the fractalkine receptor CX 3 CRl-positive cells in the glomeruli in the prolonged model were significantly higher than those in the reversible model. Then, the localization of fractalkine and the characteristics of CX 3 CR1 + cells were analyzed in glomeruli. To elucidate the significance of the fractalkine expression, we analyzed the expression in the model treated with angiotensin II receptor antagonist, candesartan. Results. Immunostaining of fractalkine was detected on endothelial cells on the fifth day, and fractalkine staining also was detected in the mesangial area on day 14. Major parts of the CX 3 CR1 + cells in the glomeruli were macrophages, especially ED3 + cells. Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction. Although the treatment did not ameliorate the morphological finding at two weeks, decreased expression of fractalkine and CX 3 CR1 + were already detected at two weeks in rats treated with candesartan. Conclusions. Fractalkine expression and the recruitment of CX 3 CR1 + cells in glomeruli might play an important role in the development of the prolonged disease. These expressions could be predictors of the prolonged disease of the mesangial proliferative glomerulonephritis.

AB - Background. We established the reversible and the prolonged models of mesangial proliferative glomerulonephritis (GN) with anti-Thy 1 antibody 1-22-3. However, the essential factors leading to the prolonged glomerular alterations have not been identified. Methods. The expressions of several chemokines and cytokines were compared in the reversible and the prolonged models. Expression of fractalkine and the number of the fractalkine receptor CX 3 CRl-positive cells in the glomeruli in the prolonged model were significantly higher than those in the reversible model. Then, the localization of fractalkine and the characteristics of CX 3 CR1 + cells were analyzed in glomeruli. To elucidate the significance of the fractalkine expression, we analyzed the expression in the model treated with angiotensin II receptor antagonist, candesartan. Results. Immunostaining of fractalkine was detected on endothelial cells on the fifth day, and fractalkine staining also was detected in the mesangial area on day 14. Major parts of the CX 3 CR1 + cells in the glomeruli were macrophages, especially ED3 + cells. Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction. Although the treatment did not ameliorate the morphological finding at two weeks, decreased expression of fractalkine and CX 3 CR1 + were already detected at two weeks in rats treated with candesartan. Conclusions. Fractalkine expression and the recruitment of CX 3 CR1 + cells in glomeruli might play an important role in the development of the prolonged disease. These expressions could be predictors of the prolonged disease of the mesangial proliferative glomerulonephritis.

UR - http://www.scopus.com/inward/record.url?scp=0036098871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036098871&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00369.x

DO - 10.1046/j.1523-1755.2002.00369.x

M3 - Article

C2 - 12028445

AN - SCOPUS:0036098871

VL - 61

SP - 2044

EP - 2057

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -